Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Annemarie Boerma"'
Autor:
Anastasia Gangaev, Yannick van Sleen, Nicole Brandhorst, Kelly Hoefakker, Bimal Prajapati, Amrita Singh, Annemarie Boerma, Marieke van der Heiden, Sjoukje F. Oosting, Astrid A. M. van der Veldt, T. Jeroen N. Hiltermann, Corine H. GeurtsvanKessel, Anne-Marie C. Dingemans, Egbert F. Smit, Elisabeth G. E. de Vries, John B. A. G. Haanen, Pia Kvistborg, Debbie van Baarle
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionResearch has confirmed the safety and comparable seroconversion rates following SARS-CoV-2 vaccination in patients with solid cancers. However, the impact of cancer treatment on vaccine-induced T cell responses remains poorly understood.M
Externí odkaz:
https://doaj.org/article/80fab91389fd443aa2a12002abce5698
Autor:
Céline Imhof, MD, A. Lianne Messchendorp, MD, PhD, Marieke van der Heiden, PhD, Carla C. Baan, PhD, Renate G. van der Molen, PhD, Ester B. M. Remmerswaal, PhD, Rory D. de Vries, PhD, Dimitri A. Diavatopoulos, PhD, Annemarie Boerma, MSc, Femke J. Bakker, BSc, Emily Oosterhout, BSc, Frederike J. Bemelman, MD, PhD, Luuk B. Hilbrands, MD, PhD, Marlies E. J. Reinders, MD, PhD, Ron T. Gansevoort, MD, PhD, Jan-Stephan Sanders, MD, PhD, Debbie van Baarle, PhD, on behalf of RECOVAC Consortium
Publikováno v:
Transplantation Direct, Vol 8, Iss 11, p e1387 (2022)
Background. Studies have shown that coronavirus disease 2019 (COVID-19) vaccination is associated with a lower humoral response in vulnerable kidney patients. Here, we investigated the T-cell response following COVID-19 vaccination in kidney patients
Externí odkaz:
https://doaj.org/article/7afa0ccb8ef14bc0b3e6b150791cf86b
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
M2-like tumor-associated macrophages promote tumor progression by establishing an immunosuppressive tumor microenvironment. The phenotype and activity of immunosuppressive macrophages are related to their mitochondrial metabolism. Thus, we studied if
Externí odkaz:
https://doaj.org/article/3ed9264caad847f1bfb6a4280ff40acd
Autor:
Georgia Koutsoumpli, Peng Peng Ip, Ilona Schepel, Baukje Nynke Hoogeboom, Annemarie Boerma, Toos Daemen
Publikováno v:
Therapeutic Advances in Vaccines and Immunotherapy, Vol 7 (2019)
Background: Antigen-specific T cell immune responses play a pivotal role in resolving acute and chronic hepatitis C virus (HCV) infections. Currently, no prophylactic or therapeutic vaccines against HCV are available. We previously demonstrated the p
Externí odkaz:
https://doaj.org/article/4b511760a15548edb19b4db2e018ff2d
Autor:
Stephanie van de Wall, Karl Ljungberg, Peng Peng Ip, Annemarie Boerma, Maria L. Knudsen, Hans W. Nijman, Peter Liljeström, Toos Daemen
Publikováno v:
OncoImmunology, Vol 7, Iss 10 (2018)
Cervical cancer develops as a result of infection with high-risk human papillomavirus (HPV) through persistent expression of early proteins E6 and E7. Our group pioneered a recombinant viral vector system based on Semliki Forest virus (SFV) for vacci
Externí odkaz:
https://doaj.org/article/26b13e6bf0844041b4a00973caa53f20
Autor:
Sjoukje F Oosting, Astrid A M van der Veldt, Rudolf S N Fehrmann, Corine H GeurtsvanKessel, Rob S van Binnendijk, Anne-Marie C Dingemans, Egbert F Smit, T Jeroen N Hiltermann, Gerco den Hartog, Mathilda Jalving, Tatjana T Westphal, Arkajyoti Bhattacharya, Faye de Wilt, Annemarie Boerma, Lisanne van Zijl, Guus F Rimmelzwaan, Pia Kvistborg, Cecile A C M van Els, Nynke Y Rots, Debbie van Baarle, John B A G Haanen, Elisabeth G E de Vries
Publikováno v:
The Lancet Oncology, 23(7), 833-835. Lancet Publishing Group
Lancet Oncology, 23(7), 833-835. ELSEVIER SCIENCE INC
Oosting, S F, van der Veldt, A A M, Fehrmann, R S N, GeurtsvanKessel, C H, van Binnendijk, R S, Dingemans, A-M C, Smit, E F, Hiltermann, T J N, den Hartog, G, Jalving, M, Westphal, T T, Bhattacharya, A, de Wilt, F, Boerma, A, van Zijl, L, Rimmelzwaan, G F, Kvistborg, P, van Els, C A C M, Rots, N Y, van Baarle, D, Haanen, J B A G & de Vries, E G E 2022, ' Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours ', The Lancet Oncology, vol. 23, no. 7, pp. 833-835 . https://doi.org/10.1016/S1470-2045(22)00203-0
Lancet Oncology, 23(7), 833-835. ELSEVIER SCIENCE INC
Oosting, S F, van der Veldt, A A M, Fehrmann, R S N, GeurtsvanKessel, C H, van Binnendijk, R S, Dingemans, A-M C, Smit, E F, Hiltermann, T J N, den Hartog, G, Jalving, M, Westphal, T T, Bhattacharya, A, de Wilt, F, Boerma, A, van Zijl, L, Rimmelzwaan, G F, Kvistborg, P, van Els, C A C M, Rots, N Y, van Baarle, D, Haanen, J B A G & de Vries, E G E 2022, ' Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours ', The Lancet Oncology, vol. 23, no. 7, pp. 833-835 . https://doi.org/10.1016/S1470-2045(22)00203-0
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3faeb72ddc1ab94cc99e2975667c2840
https://research.vumc.nl/en/publications/ce00c378-f94b-45ef-b9a7-6ef58bfc57d2
https://research.vumc.nl/en/publications/ce00c378-f94b-45ef-b9a7-6ef58bfc57d2
Autor:
Stephanie van de Wall, Janneke M. Meulenberg, Baukje Nynke Hoogeboom, Jessica Sluis, Coba J. van Zanten, Joke Regts, Marco de Bruyn, Toos Daemen, Fenne L. Komdeur, Jos G. W. Kosterink, Amrita Singh, Ed Schuuring, Jan Wilschut, Derk P. Allersma, Ruben Marra, Annemarie Boerma, Ate G.J. van der Zee, Annelies Jorritsma-Smit, Cesar Oyarce, Hans W. Nijman, N Werner, R. Yigit, S. T. Paijens
Publikováno v:
Mol Ther
Molecular Therapy, 29(2), 611-625. CELL PRESS
Molecular therapy, 29(2), 611-625. Nature Publishing Group
Molecular Therapy
Molecular Therapy, 29(2), 611-625. CELL PRESS
Molecular therapy, 29(2), 611-625. Nature Publishing Group
Molecular Therapy
A first-in-human phase I trial of Vvax001, an alphavirus-based therapeutic cancer vaccine against human papillomavirus (HPV)-induced cancers was performed assessing immunological activity, safety, and tolerability. Vvax001 consists of replication-inc
Autor:
Annemarie Boerma, Toos Daemen, Ilona Schepel, Georgia Koutsoumpli, Peng Peng Ip, Baukje Nynke Hoogeboom
Publikováno v:
Therapeutic Advances in Vaccines and Immunotherapy, 7, 1-13. SAGE Publishing
Therapeutic Advances in Vaccines and Immunotherapy, Vol 7 (2019)
Therapeutic Advances in Vaccines and Immunotherapy
Therapeutic Advances in Vaccines and Immunotherapy, Vol 7 (2019)
Therapeutic Advances in Vaccines and Immunotherapy
Background: Antigen-specific T cell immune responses play a pivotal role in resolving acute and chronic hepatitis C virus (HCV) infections. Currently, no prophylactic or therapeutic vaccines against HCV are available. We previously demonstrated the p
Publikováno v:
OncoImmunology, 10(1):1898753. Taylor & Francis Group
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
M2-like tumor-associated macrophages promote tumor progression by establishing an immunosuppressive tumor microenvironment. The phenotype and activity of immunosuppressive macrophages are related to their mitochondrial metabolism. Thus, we studied if
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f07686dd1d766525bdd6b92f50fdb191
https://research.rug.nl/en/publications/a26084f8-ea7c-4e3d-888d-3711e04d60f3
https://research.rug.nl/en/publications/a26084f8-ea7c-4e3d-888d-3711e04d60f3
Autor:
Peng Peng Ip, Hans W. Nijman, Stephanie van de Wall, Maria L. Knudsen, Karl Ljungberg, Toos Daemen, Peter Liljeström, Annemarie Boerma
Publikováno v:
Oncoimmunology
Oncoimmunology, 7, e1487913
Oncoimmunology, 7, 10, pp. e1487913
OncoImmunology, Vol 7, Iss 10 (2018)
OncoImmunology, 7(10):e1487913. Taylor & Francis Group
Oncoimmunology, 7, e1487913
Oncoimmunology, 7, 10, pp. e1487913
OncoImmunology, Vol 7, Iss 10 (2018)
OncoImmunology, 7(10):e1487913. Taylor & Francis Group
Contains fulltext : 200325.pdf (Publisher’s version ) (Open Access) Cervical cancer develops as a result of infection with high-risk human papillomavirus (HPV) through persistent expression of early proteins E6 and E7. Our group pioneered a recombi